These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36154597)

  • 1. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
    Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
    Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
    Bergsma EJ; Elgawly M; Mancuso D; Orr R; Vuskovich T; Seligson ND
    Ann Pharmacother; 2024 Apr; 58(4):407-415. PubMed ID: 37466080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
    Italiano A; Bellera C; D'Angelo S
    J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
    Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
    ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.
    Li Y; Liu Y; Qu Y; Chen X; Qu X; Ye Y; Du X; Cheng Y; Xu M; Zhang H
    Front Immunol; 2022; 13():832593. PubMed ID: 35603147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
    Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
    BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
    Brahmi M; Vanacker H; Dufresne A
    Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
    Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
    J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
    Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
    Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
    Su H; Yu C; Ma X; Song Q
    Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
    Chen AP; Sharon E; O'Sullivan-Coyne G; Moore N; Foster JC; Hu JS; Van Tine BA; Conley AP; Read WL; Riedel RF; Burgess MA; Glod J; Davis EJ; Merriam P; Naqash AR; Fino KK; Miller BL; Wilsker DF; Begum A; Ferry-Galow KV; Deshpande HA; Schwartz GK; Ladle BH; Okuno SH; Beck JC; Chen JL; Takebe N; Fogli LK; Rosenberger CL; Parchment RE; Doroshow JH
    N Engl J Med; 2023 Sep; 389(10):911-921. PubMed ID: 37672694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.